Early Access — free while we kick the tires
EdgarHawk

Strobeck Matthew

Director

Director
2 filings analyzed · 2 companies · Latest 2026-02-13

Companies

Company Buys Sells Direction
QuidelOrtho Corp QDEL 1 0 Net buying
BIODESIX INC BDSX 2 0 Net buying

Activity

February 2026
2026-02-13 QuidelOrtho Corp QDEL
high
Buy
10,000 shares
$239,586
Significance 7/10

Director Strobeck purchases 10,000 shares of QDEL at $23.96; cluster buy pattern with 2 other insiders in past 14 days

Director Matthew Strobeck acquired 10,000 shares at $23.96 on 2026-02-13, increasing his holdings by 56.3% to 27.8K shares total. This transaction is part of a cluster pattern with 2 other insiders buying within the past 14 days, which reflects coordinated insider accumulation activity. The purchase occurs while the stock trades at $23.58, down -45.0% from its 52-week high of $42.89 and down -31.3% over the past 30 days, yet the company reported negative net income of $-733.0M on revenue of $699.9M and annual revenue decline of -7.2%. Across his cross-ticker open-market trading history, Strobeck's prior buys have averaged 90-day returns of +885.4% with a 66.67% win rate, providing historical context that his buying activity has been profitable, though this metric reflects his track record across multiple securities rather than QuidelOrtho-specific performance.

November 2024
2024-11-06 BIODESIX INC BDSX
medium
Buy
40,000 shares
$55,916
Significance 6/10

Director Strobeck bought 40,000 shares at $1.40 on 2024-11-05 ($55,916.00); 4 other insiders also bought within 14 days.

Matthew Strobeck, a Director at Biodesix, executed 2 separate purchases totaling 40,000 shares for $55,916.00 at $1.40 per share on 2024-11-05, raising his holdings to 2,606,879 shares. The notable context is that this purchase occurred when the stock was trading at $1.40, well below the current price of $26.60 and near the bottom of the 52-week range of $24.00–$42.40. The transaction is part of a broader cluster pattern: 4 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence at these price levels. However, Strobeck's cross-ticker track record shows a -29.1% average 30-day return and -33.8% average 90-day return across prior purchases (with a 0.00% win rate), indicating his recent buy decisions have not generated positive returns. The company remains unprofitable with a net loss of $10,258,000.00 in the latest quarter, though it achieved 28.5% annual revenue growth, presenting a mixed fundamental picture.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access